On February 18, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential opinion in an appeal by Canfield Scientific, Inc. (Canfield) from the decision of the U.S. Patent Trial and Appeal Board (PTAB or Board) on inter partes review (IPR) of U.S. Patent No. 7,359,748 (the ‘748 patent) owned by Melanoscan, LLC. The court held that the Board erred in ruling that all the claims of the ‘748 patent were patentable. The decision was reversed with respect to the independent claims and vacated and remanded as to the dependent claims.
Recent Posts
- Trump Administration Adopts Innovation-Killing Biden NIH Licensing Guidelines
- Amici Back AI Company’s Third Circuit Appeal of Summary Judgment for Thomson Reuters
- The AI Revolution: From Drilling to Algorithms, Inventing an Energy Future / IPWatchdog Unleashed
- CAFC Affirms Obviousness of Vehicle ID Claims, Finds Substitute Claims Ineligible Under Section 101
- U.S. Patent Litigation Trends in 2025: Patterns Behind the Numbers
